|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:1373-1381
© 2006 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
a Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
b Laboratory and Transfusion Medicine, Heart Center North Rhine-Westphalia, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
c Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany.
Received for publication May 2, 2005; revisions received December 18, 2005; accepted for publication January 10, 2006. * Address for reprints: Aly El-Banayosy, MD, Heart Center NRW, Georgstrasse 11, Bad Oeynhausen, Germany, 32545. (Email: abanayosy{at}hdz-nrw.de).
OBJECTIVES: Patients receiving mechanical circulatory support are at risk for the development of heparin-induced thrombocytopenia due to the prolonged postoperative use of heparin. We evaluated their antibody status and outcome.
METHODS: Between 2003 and 2004, 115 patients received mechanical circulatory support for more than 5 days. Blood samples from postoperative day 7 were retrospectively analyzed for antiplatelet factor 4/heparin antibodies and heparin-induced platelet activation.
RESULTS: Overall, 12 (10.6%) patients had heparin-induced thrombocytopenia as defined by in vitro platelet activation, 28 (24.8%) had nonactivating antibodies, and 73 (64.6%) were classified as negative for antibodies. Patients positive for heparin-induced thrombocytopenia had the highest levels of antiplatelet factor 4/heparin immunoglobulin G antibodies. Freedom from thromboembolism was 33%, 33%, and 16% at 1, 3, and 6 months for positive patients, 77%, 68%, and 55% for negative patients (P < .001), and 70%, 53%, and 53% for patients with nonactivating antibodies (P = .068), respectively. The relative risk for thromboembolism in antibody positive patients peaked in the first month of support (odds ratio 7.46, P = .002). Independent risk factors for thromboembolic events included higher antiplatelet factor 4/heparin antibody titers, female gender, and higher fibrinogen levels.
CONCLUSION: Heparin-induced thrombocytopenia was more prevalent in patients receiving mechanical circulatory support than in other cardiac patients. Frequent antibody screening is recommended due to the increased risk of thromboembolism. Heparin alternatives should be subjected to clinical trials in these high-risk patients.
This article has been cited by other articles:
![]() |
T. E. Warkentin, A. Greinacher, and A. Koster Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann. Thorac. Surg., May 1, 2009; 87(5): 1633 - 1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Weiss, L. W. Miller, and F. D. Pagani Continuous-Flow Ventricular Assist Device N. Engl. J. Med., November 29, 2007; 357(22): 2305 - 2306. [Full Text] [PDF] |
||||
![]() |
A. Koster Reply Ann. Thorac. Surg., October 1, 2007; 84(4): 1423 - 1424. [Full Text] [PDF] |
||||
![]() |
J. N. Schroder, M. A. Daneshmand, N. R. Villamizar, R. P. Petersen, L. J. Blue, I. J. Welsby, A. J. Lodge, T. L. Ortel, J. G. Rogers, and C. A. Milano Heparin-Induced Thrombocytopenia in Left Ventricular Assist Device Bridge-to-Transplant Patients Ann. Thorac. Surg., September 1, 2007; 84(3): 841 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Warkentin and M. A. Crowther When is HIT Really HIT? Ann. Thorac. Surg., January 1, 2007; 83(1): 21 - 23. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |